• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Professional Introduction to 3-(1H-Indazol-1-yl)propanenitrile (CAS No. 23300-94-9)

3-(1H-Indazol-1-yl)propanenitrile, a compound with the chemical formula C₁₀H₈N₂, is a significant molecule in the field of pharmaceutical chemistry and drug discovery. This compound, identified by its CAS number CAS No. 23300-94-9, has garnered attention due to its structural properties and potential applications in medicinal chemistry. The indazole moiety, a key structural feature, is known for its role in various biological activities, making this compound a valuable scaffold for developing new therapeutic agents.

The indazole ring system is a heterocyclic aromatic compound that consists of a benzene ring fused to a pyrazole ring. This unique structure imparts distinct electronic and steric properties, which can be exploited in the design of molecules with specific biological targets. In the case of 3-(1H-Indazol-1-yl)propanenitrile, the presence of a nitrile group at the propyl chain enhances its reactivity and versatility, allowing for further functionalization and derivatization.

Recent advancements in drug discovery have highlighted the importance of indazole derivatives in addressing various therapeutic challenges. Studies have demonstrated that compounds containing the indazole scaffold exhibit a wide range of biological activities, including anti-inflammatory, anticancer, and antimicrobial properties. The nitrile group in 3-(1H-Indazol-1-yl)propanenitrile further contributes to its potential as a pharmacophore by enabling interactions with biological targets through hydrogen bonding or coordinate covalent binding.

In the context of current research, 3-(1H-Indazol-1-yl)propanenitrile has been investigated for its role in modulating enzyme activity and receptor binding. For instance, it has been shown to interact with certain kinases and transcription factors, which are crucial in regulating cellular processes. The ability of this compound to bind to these targets suggests its potential in developing treatments for diseases such as cancer and neurodegenerative disorders. Furthermore, its structural similarity to known active pharmaceutical ingredients (APIs) makes it an attractive candidate for structure-based drug design.

The synthesis of 3-(1H-Indazol-1-yl)propanenitrile involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions between indazole derivatives and nitrile-forming agents, followed by functional group transformations to introduce the propyl chain. Advances in synthetic methodologies have enabled more efficient and scalable production of this compound, facilitating its use in both academic research and industrial applications.

One of the key advantages of 3-(1H-Indazol-1-yl)propanenitrile is its flexibility in chemical modification. The presence of both the indazole ring and the nitrile group provides multiple sites for further derivatization, allowing chemists to tailor the molecule's properties for specific applications. This flexibility has led to numerous derivative compounds being explored for their pharmacological effects. For example, analogs with different substituents on the indazole ring or varying lengths of the propyl chain have been synthesized to evaluate their biological activity and selectivity.

The pharmacokinetic profile of 3-(1H-Indazol-1-yl)propanenitrile is another critical aspect that has been studied extensively. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is essential for determining its suitability as a drug candidate. Preliminary studies suggest that this compound exhibits reasonable oral bioavailability and metabolic stability, which are favorable characteristics for further development into an oral therapeutic agent.

In conclusion, 3-(1H-Indazol-1-yl)propanenitrile (CAS No. 23300-94-9) is a promising compound with significant potential in pharmaceutical research and development. Its unique structural features, including the indazole moiety and the nitrile group, make it a versatile scaffold for designing molecules with diverse biological activities. Ongoing research continues to explore its applications in treating various diseases, highlighting its importance as a building block in medicinal chemistry.

• 889885-01-2(1H-Indazole-1-propanol)
• 872364-58-4(1H-Indazole, 1-(3-butynyl)-)
• 43120-22-5(Indazole; 1H-form, N1-Et)
• 933744-08-2(3-(1H-Indazol-1-yl)propan-1-amine)
• 1046454-19-6(1-propyl-1H-Indazol-5-amine)
• 765914-94-1(1H-Indazol-5-ol, 1-(2-methylpropyl)-)
• 872364-56-2(2H-Indazole, 2-(3-butynyl)-)
• 1280786-76-6(5-Bromo-1-propylindazole)
• 170643-05-7(1H-Indazole-1-propanal)
• 890534-66-4(1H-Indazole, 1-cyclopropyl-)